TYK MEDICINES-B (02410) rose more than 12% intraday, with gains narrowing to 7.16% by press time at HK$14.21, recording a turnover of HK$132 million. The surge follows heightened market attention on the company's core product, TY-9591 (Aidotinib), after its key Phase II clinical trial for non-small cell lung cancer (NSCLC) with brain metastasis drew significant interest at the World Conference on Lung Cancer in September.

TY-9591, a highly selective small-molecule inhibitor targeting EGFR classical mutations, completed enrollment of 224 patients for conditional approval in November 2024. The company submitted a Pre-NDA application in April 2025 and expects to file a formal New Drug Application (NDA) in Q4 2025.

Analysts note that third-generation EGFR-TKIs have become foundational in lung cancer targeted therapy, with intense R&D competition. Post-resistance to EGFR-TKIs remains a critical challenge, making next-line solutions a high-value investment focus.